Acuut inversieletsel van de enkel

The clinical impact of platelet refractoriness: correlation with bleeding and survival

“…In the first analysis of this study, we already showed that patientrelated factors were the main determinants of transfusion failure, independent of product factors such as storage medium and storage time. 16 This is in agreement with a recently published study showing that storage duration of both buffy-coat PCs and apheresis PCs only explained for less than 4 percent of the variation in CCI and transfusion interval. 20 The relationship between PLT count and bleeding has been reported with conflicting results.…”

“…Between October 2003 and April 2005, a randomized controlled trial, testing the clinical efficacy of PLTs stored in plasma compared to PLT additive solution (PAS II), was performed. 16 For the current analysis, only patients randomized in the Leiden University Medical Center were evaluated. All patients older than 18 years who needed or were expected to need more than two PC transfusions were eligible.…”

“…The 1and 24-hour CCIs were calculated according to the method described in our previous study. 16 PLT transfusion refractoriness or failure was defined as a 1-hour CCI below 7.5 and/or a 24-hour CCI below 4.5. In patients experiencing repeated episodes of refractoriness without an apparent clinical cause, tests for the existence of HLA and/or HPA alloantibodies (PAK12, GTI, Waukesha, WI) were performed.…”

Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood–derived platelet concentrates suspended in plasma prepared with photochemical treatment

“…Recently, it has been shown that PLT ADP response deteriorates in PLTs stored in synthetic storage media (PAS-II or Composol). 20 Kerkhoffs and coworkers, 21 however, have shown that the count increments of PLTs suspended in mixtures of plasma and ASs (PAS-II) were within therapeutic ranges, and the acute transfusion reaction rate was lower than for PLT components in 100 percent plasma. Use of any AS would require local regulatory clearance.…”

A comparison of volume‐reduced versus standard HLA/HPA–matched apheresis platelets in alloimmunized adult patients

“…We anticipate a reduced response in the VR-AP group because unpublished data from our center have shown an approximate 15% loss in PLTs for transfusion due to the process of volume reduction. Further because there have been a number of reports about the efficacy of replacing 70% of the plasma with synthetic storage media in lowering the frequency of adverse reactions to PLTs, [14][15][16][17] we also investigated the reports of adverse transfusion reactions.…”